Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a
global population of more than 35 million people living with HIV, there is intense interest in …

One of the most explored therapeutic approaches aimed at eradicating HIV-1 reservoirs is
the “shock and kill” strategy which is based on HIV-1 reactivation in latently-infected cells …

Human immunodeficiency virus type 1 (HIV-1) eradication is prevented by the establishment
on infection of cellular HIV-1 reservoirs that are not fully characterized, especially in genital …

Despite years of fully suppressive antiretroviral therapy (ART), HIV persists in its hosts and is
never eradicated. One major barrier to eradication is that the virus infects multiple cell types …

Human immunodeficiency virus (HIV) persistence in latently infected resting memory CD4+
T-cells is the major barrier to HIV cure. Cellular histone deacetylases (HDACs) are important …

Reversal of HIV-1 latency by small molecules is a potential cure strategy. This approach will
likely require effective drug combinations to achieve high levels of latency reversal. Using …

The implementation of antiretroviral therapy 23 years ago has rendered HIV infection
clinically manageable. However, the disease remains incurable, since it establishes latent …

Background Quantifying latently infected cells is critical to evaluate the efficacy of
therapeutic strategies aimed at reducing the size of the long-lived viral reservoir, but the low …

Combinatory antiretroviral therapy (cART) reduces human immunodeficiency virus type 1
(HIV-1) replication but is not curative because cART interruption almost invariably leads to a …

Latency reversal agents (LRAs) have proven to induce HIV-1 transcription in vivo but are
ineffective at decreasing the size of the latent reservoir in antiretroviral treated patients. The …